Published in Women's Health Weekly, December 22nd, 2005
Vernalis will pay an initial consideration of US$29.5 million, payable in Vernalis shares, and assume certain of Cita's liabilities. Vernalis will also pay deferred consideration in installments of up to US$35 million in either shares or cash (at Vernalis' option) dependent upon achieving certain milestones in respect of the development of Cita's clinical drug candidates CNP1512 and CNP3381. A total of UKP 15.3 million (US$26.2 million) (before expenses) of the initial share consideration has been conditionally placed outside...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly